Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan Plans Incentives To Pharmacists To Push Generic Drugs (Japan)

This article was originally published in PharmAsia News

Executive Summary

Japan's health ministry plans to begin next April providing incentives to pharmacists to get them to push generic versions instead of brand-name drugs. An official says the government, as part of a medical cost-cutting effort, has drafted the plan to be included in a broader review of its medical service fee system. The incentive involves offering pay to pharmacists whose generics sales are at least 30 percent of the medicines they sell. The ministry expects health care spending to grow by 74 percent by 2025. (Click here for more ) "Japan Plans Generic Drug Incentives: Ministry" China Post (Taiwan) (12/7/07)

You may also be interested in...



Japan Looking To Western Countries For Generic Drug Utilization Tips

Japan's Ministry of Health, Labor and Welfare will send a research group to the U.S., U.K. and France in February, to study price setting and logistical systems being used in the pharmaceutical industries there, the MHLW announced Jan. 29.The research will focus on how to promote generic drugs in Japan to bring new ideas to the drug re-pricing discussions in April, said the MHLW

Pink Sheet Podcast: Woodcock To Be Acting US FDA Chief, Key Staff Depart, Political Donations Shift

Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class of Early Cancer Detection Test

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

UsernamePublicRestriction

Register

LL1129367

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel